Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. - Wikidata - awgldk - TriplyDB

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

http://www.wikidata.org/entity/Q43055328

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Current challenges and novel treatment strategies in double hit lymphomas MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management The emerging role of Twist proteins in hematopoietic cells and hematological malignancies Biology of double-hit B-cell lymphomas Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update The role of aberrant proteolysis in lymphomagenesis Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.Role of MYC in B Cell Lymphomagenesis.Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas My treatment approach to patients with diffuse large B-cell lymphoma.C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.GSTT1 deletion is related to polycyclic aromatic hydrocarbons-induced DNA damage and lymphoma progression C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2.Practice gaps and barriers to optimal care of hematologic malignancies in the United States.The histological classification of diffuse large B-cell lymphomas Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Aggressive B-cell lymphomas: how many categories do we need?CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas.Grey zone lymphomas: lymphomas with intermediate features.Management of Patients with MYC-Altered Lymphomas.Genetic lesions in diffuse large B-cell lymphomas Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma Cell of origin of transformed follicular lymphoma Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.

P2860

Q24597424-16E80CDB-3055-469A-974E-B740B2580FC3 Q26770385-F7A54F2D-FFD8-4979-AA71-F0FCAADDEEBE Q26785379-578F5153-E944-4B4D-97B7-5DC9DCD55AF2 Q26822434-7B2CD410-19F3-49FB-B569-383E1EE187B4 Q26825581-7541640A-2450-40C7-8465-0B58498592A1 Q27304386-C26DED23-76AB-456A-94D4-C80833655871 Q28067817-C3ABE47E-3452-495A-AF0E-B5765F549C4D Q28078869-999C393D-65E9-4D54-9CD3-B2C8FF4B74F3 Q28084404-C5B1E980-A755-429D-9AE9-A3D9373C193D Q28256567-EB54898B-8CBC-45FB-8F55-882D59F0E563 Q30275206-C5E4E917-8F88-42CB-BE63-CD162DE11BAE Q33440896-01CBE3CD-2FD7-47BE-85BF-474031C57B13 Q33608499-537E5B1C-7D98-425A-B439-A34882809B48 Q33670880-F56CA762-5576-4010-9F0B-4A3AE9ADBD98 Q33846801-64124F2F-B4ED-4B1D-87AE-DE9E1325A7AB Q34000188-B913F8E4-A689-45E8-8702-8A827F754A79 Q34236713-E796B3AF-EB78-4C52-8824-AD93BEF9FA9C Q34251964-816BA66C-D324-48DC-8448-89036B0CD625 Q34371250-1F81B38E-423D-4502-B28B-6547CB6699B5 Q34882773-7145C8E6-309C-4276-8C3D-71E9C4D2FEC3 Q34918948-A4BA9417-ED7B-4EF7-9E7F-55C0FF1C76E9 Q35030096-33704312-5BB4-45A4-850E-24853AD75179 Q35107033-7BD49D95-592B-4314-924C-B70346BA304B Q35150618-C5E07B70-4B74-4162-90D5-BA4FA17C08C3 Q35180822-671C731E-F0E2-440A-B721-D38A422323C0 Q35207616-2B773E3F-8660-4AE3-A12E-6A3759CCFF3A Q35218051-9F17BB0B-BCF4-45ED-8ACF-296A0C37D855 Q35384536-76FC1EE4-FE2F-42D7-BC74-8FAC98F2C04C Q35527893-A76581C5-A2DE-41F4-9D32-DE0061FC845A Q35640007-51E821BE-D6B4-4CBB-8056-2183A55F21B9 Q35881523-1C0159E4-BF67-415F-879A-BFEF159DAA0D Q35882774-91143758-433B-4D55-9803-08B213323E1B Q35960027-AB466731-0BF8-426D-AE79-F0FE9E52C4B1 Q35974341-D5C7572F-0541-437A-B0C3-B70E31E965C6 Q36022544-0E07E7A2-F888-49EA-A690-35C3F23FA49A Q36210875-9D0FC289-85D8-4B70-9D21-2ACF71647C89 Q36225164-E422D12B-5EAC-48F3-9EFA-131EE9B306F0 Q36267666-4B1D3528-F250-4077-A1C7-8354E543BE7C Q36280547-F739C1C0-D751-4F91-B480-47094FB0490C Q36302961-A2E0B2CB-7B5A-4473-8ECF-AE2C4ABBDD1F

P2860

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

http://www.wikidata.org/entity/Q43055328

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@en

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@nl

type

label

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@en

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@nl

prefLabel

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@en

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@nl

P1433

Q43055328-A46A54AD-16B0-40D0-8356-1F3BD4A8BE97

P1476

Q43055328-D3DD8EA0-9B67-4973-84A9-83267312669C

P2093

Q43055328-05C4338E-AF34-4E68-AEB6-B2BFF891BDEC

Q43055328-08499867-F9CA-4D8A-8A7A-3C7C74CD4362

Q43055328-0ED91EC6-5620-4025-A81E-86E61EDA657E

Q43055328-1901ED9E-2C09-4A82-B28E-CCBDB79E6812

Q43055328-528E9DF9-A197-46DB-950E-B50C14D9FDAE

Q43055328-7534BF22-C593-4851-905B-40A5E419990A

Q43055328-A3ABE6FE-D5B3-4A44-AC10-8E0DCEE88AF3

Q43055328-B2BE9E87-7D15-4D2E-9A08-F8BB31677527

P304

Q43055328-894F7FB3-52CD-4078-A94E-0FAE0B359EA7

P31

Q43055328-6B5FB70E-2E71-4165-B785-47CEF01454B0

P356

Q43055328-ABC24A1C-4957-4C4F-8835-56E8AEBBEE0D

P407

Q43055328-F8F7664B-6EC0-4617-AB29-F1061AA79153

P433

Q43055328-3ABE9AF2-A4CB-47FB-93BE-07C376AC0294

P478

Q43055328-C8E45632-9E22-4541-868B-DD474147539D

P577

Q43055328-8AA10C6D-58E4-41C7-A60C-D90EF76ED8EE

P698

Q43055328-FB720492-5C3B-472F-9B86-1FF591382B8C

P921

Q43055328-86F240B9-6275-4203-B842-174447E960B0

P356

JCO.2009.26.3947

P1433

Journal of Clinical Oncology

P1476

Rearrangement of MYC is associ ...... eated in the era of rituximab.

@en

P2093

Alex Smith

http://www.w3.org/2001/XMLSchema#string

Andrew Jack

http://www.w3.org/2001/XMLSchema#string

Eve Roman

http://www.w3.org/2001/XMLSchema#string

Kathryn Turner

http://www.w3.org/2001/XMLSchema#string

Roger Owen

http://www.w3.org/2001/XMLSchema#string

Russell Patmore

http://www.w3.org/2001/XMLSchema#string

Sharon Barrans

http://www.w3.org/2001/XMLSchema#string

Simon Crouch

http://www.w3.org/2001/XMLSchema#string

P304

3360-3365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.3947

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20498406

http://www.w3.org/2001/XMLSchema#string

P921